Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Hampshire Health Report.
Press releases published on August 5, 2025
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 5, 2025
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its second quarter ended June 30, …
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
GlobeNewswire
·
August 5, 2025
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease – – Pro forma cash and cash equivalents from aggregate proceeds anticipated …
CorVel Announces Revenues and Earnings
GlobeNewswire
·
August 5, 2025
FORT WORTH, Texas, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2025. Revenues for the quarter were $235 million, an increase from $212 million in the June quarter of 2024. …
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
August 5, 2025
BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and …
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
GlobeNewswire
·
August 5, 2025
Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume growth for the first time and expects continued QOQ …
Amneal Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 5, 2025
‒ Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full Debt Refinancing Reduces Interest Cost …
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
GlobeNewswire
·
August 5, 2025
Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK) characteristics AIC468 was safe and well tolerated in all …
CancerVax Successfully Disguises Cancer Cells and Tricks Immune Cells into Attacking Them
GlobeNewswire
·
August 5, 2025
LEHI, Utah, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it has proven a major foundational hypothesis. …
Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market
GlobeNewswire
·
August 5, 2025
Has more than 30 years of experience bringing innovations to market, including one of the world’s first drug-eluting coronary stents at Angiotech Pharma Appointment adds world-class capabilities to Tensive as the company approaches pivotal clinical trial …
Tensive nomina Bill Hunter, esperto riconosciuto nei dispositivi medici, Presidente del CdA, mentre il suo scaffold bioassorbibile per la ricostruzione del seno post-tumore si avvicina alla commercializzazione
GlobeNewswire
·
August 5, 2025
Oltre 30 anni di esperienza nell’introdurre innovazioni sul mercato, incluso uno dei primi stent coronarici a rilascio di farmaco al mondo sviluppato con Angiotech Pharma La nomina rafforza le competenze di Tensive in vista dei prossimi fondamentali …
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
GlobeNewswire
·
August 5, 2025
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for …
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
GlobeNewswire
·
August 5, 2025
Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in Japan Triggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, France …
Nicox annonce l’initiation par son partenaire Kowa d’un essai clinique de Phase 3 pour NCX 470 au Japon
GlobeNewswire
·
August 5, 2025
5 août 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que son partenaire exclusif au Japon, Kowa, a …
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
GlobeNewswire
·
August 5, 2025
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader …
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
GlobeNewswire
·
August 5, 2025
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …